FDA Awards Priority Review Voucher to Krystal Biotech for Rare Pediatric Disease Product VYJUVEK

Summary

The FDA has issued a priority review voucher to Krystal Biotech, Inc. for its rare pediatric disease product VYJUVEK, following a review of the product's eligibility under the Federal Food, Drug, and Cosmetic Act.